Astria Therapeutics (ATXS) Competitors $6.65 -0.03 (-0.45%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$6.66 +0.01 (+0.15%) As of 08/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. SDGR, EVO, JANX, ETNB, EWTX, WVE, ABCL, HROW, VERA, and ARDXShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Schrodinger (SDGR), Evotec (EVO), Janux Therapeutics (JANX), 89BIO (ETNB), Edgewise Therapeutics (EWTX), WAVE Life Sciences (WVE), AbCellera Biologics (ABCL), Harrow (HROW), Vera Therapeutics (VERA), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Schrodinger Evotec Janux Therapeutics 89BIO Edgewise Therapeutics WAVE Life Sciences AbCellera Biologics Harrow Vera Therapeutics Ardelyx Schrodinger (NASDAQ:SDGR) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Which has better valuation and earnings, SDGR or ATXS? Astria Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M6.66-$187.12M-$2.48-7.60Astria TherapeuticsN/AN/A-$94.26M-$1.87-3.56 Does the media refer more to SDGR or ATXS? In the previous week, Schrodinger had 11 more articles in the media than Astria Therapeutics. MarketBeat recorded 17 mentions for Schrodinger and 6 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.72 beat Schrodinger's score of 0.62 indicating that Astria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Astria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of SDGR or ATXS? 79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 21.0% of Schrodinger shares are owned by insiders. Comparatively, 4.5% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, SDGR or ATXS? Schrodinger has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Is SDGR or ATXS more profitable? Astria Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Schrodinger's return on equity of -45.70% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Astria Therapeutics N/A -47.18%-31.26% Do analysts prefer SDGR or ATXS? Schrodinger currently has a consensus target price of $32.75, suggesting a potential upside of 73.74%. Astria Therapeutics has a consensus target price of $29.00, suggesting a potential upside of 336.09%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Astria Therapeutics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryAstria Therapeutics beats Schrodinger on 10 of the 16 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$376.98M$2.99B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-3.5619.9630.4025.31Price / SalesN/A344.97444.45101.55Price / CashN/A40.7837.7258.50Price / Book1.687.658.306.01Net Income-$94.26M-$54.75M$3.26B$265.10M7 Day Performance-4.73%0.95%1.53%1.39%1 Month Performance4.40%8.12%3.73%2.43%1 Year Performance-36.61%10.97%41.02%24.74% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics2.1688 of 5 stars$6.65-0.4%$29.00+336.1%-31.9%$376.98MN/A-3.5630News CoverageEarnings ReportSDGRSchrodinger2.978 of 5 stars$18.63-3.0%$32.75+75.8%+1.2%$1.41B$207.54M-7.51790Earnings ReportAnalyst RevisionEVOEvotec2.3272 of 5 stars$3.81-3.1%$5.90+54.9%+28.3%$1.40B$862.40M0.004,827JANXJanux Therapeutics2.6457 of 5 stars$22.67-0.7%$91.89+305.3%-33.7%$1.37B$10.59M-12.5930Earnings ReportAnalyst RevisionETNB89BIO1.9392 of 5 stars$8.77-4.3%$26.29+199.7%+15.6%$1.34BN/A-2.4340News CoverageEarnings ReportAnalyst RevisionEWTXEdgewise Therapeutics1.9595 of 5 stars$12.99+2.4%$41.60+220.2%-21.5%$1.34BN/A-8.3860Earnings ReportAnalyst RevisionWVEWAVE Life Sciences4.7368 of 5 stars$8.10+0.1%$20.27+150.2%+57.4%$1.29B$108.30M-9.00240ABCLAbCellera Biologics3.225 of 5 stars$4.50+5.9%$8.00+77.8%+62.0%$1.27B$28.83M-8.18500Earnings ReportHROWHarrow2.526 of 5 stars$33.74-2.0%$63.83+89.2%-1.9%$1.26B$199.61M-60.25180Earnings ReportGap UpHigh Trading VolumeVERAVera Therapeutics2.8752 of 5 stars$20.17+1.9%$63.00+212.3%-41.0%$1.26BN/A-5.6340ARDXArdelyx4.2991 of 5 stars$5.40+3.6%$11.50+113.0%-3.8%$1.26B$333.61M-23.4890Options Volume Related Companies and Tools Related Companies Schrodinger Competitors Evotec Competitors Janux Therapeutics Competitors 89BIO Competitors Edgewise Therapeutics Competitors WAVE Life Sciences Competitors AbCellera Biologics Competitors Harrow Competitors Vera Therapeutics Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access